Potential effect of the administration of substance P and allergen therapy on immunoglobulin E-mediated allergic reactions in human subjects

Journal of Laboratory and Clinical Medicine

Volumn 133, Issue 2, 1999, Pages 189-199

  Patterson, Roy ^a   Harris, Kathleen E ^b   Grammer, Leslie C ^b   Greenberger, Paul A ^b   Ditto, Anne M ^b   Shaughnessy, Martha A ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0033082177     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(99)90012-4     Document Type: Article

References (51)

1. 1. Patterson R, Harris KE. Substance P and IgE-mediated allergy. I. Transient increase in airway responsiveness to allergen in primates. Allergy Proc 1993;14:49-51.
2. 2. Patterson R, Harris KE. Substance P and IgE-mediated allergy. II. Reduction of rhesus IgE antibody following aerosol exposure to substance P and allergen. Allergy Proc 1993;14:53-9.
3. 3. Booth BH. Diagnosis of immediate hypersensitivity. In: Patterson R, Grammer LC, Greenberger PA, editors. Allergic diseases: diagnosis and management. 5th ed. Philadelphia: Lippincott-Raven; 1997. p. 177-9.
4. 50 EAL method (intradermal dilution for 50 mm sum of erythema determines bioequivalent allergy units). In: Methods of the Allergenics Products Testing Laboratory, LIB, DAPP, CBER, FDA, Food and Drug Administration, docket no. 94N-0012, October 1993, p. 91-114.
5. 5. Chai H, Farr RS, Froehlich LA, Mathison DA, McLean JA, Rosenthal RR, et al. Standardization of bronchial inhalation challenge procedures. J Allergy Clin Immunol 1975;56:323-7.
6. 6. Voller A, Bidwell DE, Bartlett A. Enzyme immunoassays in diagnostic medicine: theory and practice. Bull WHO 1976;53:55-65.
7. 7. Sepulveda R, Longbottom JL, Pepys J. Enzyme-linked immunosorbent assays (ELISA) for IgG and IgE antibodies to protein and polysaccharide antigens of Aspergillus fumigatus. Clin Allergy 1979;9:359-71.
8. 8. Patterson R, Harris KE. Models of asthma. In: Patterson R, Grammer LC, Greenberger PA, editors. Allergic diseases: diagnosis and management. 5th ed. Philadelphia: Lippincott-Raven; 1997. p. 41-8.
9. 2 on the airways of rhesus monkeys. J Allergy Clin Immunol 1980;65:269-73.
10. 4 in rhesus monkeys. Int Arch Allergy Appl Immunol 1983;71:156-60.
11. 11. Patterson R, Harris KE. The activity of aerosolized and intracutaneous synthetic platelet activating factor (AGEPC) in rhesus monkeys with IgE-mediated airway responses and normal monkeys. J Lab Clin Med 1983;102:933-8.
12. 12. Patterson R, Harris KE, Lee ML, Houlihan WJ. Inhibition of rhesus monkey airway and cutaneous responses to platelet-activating factor (PAF) (AGEPC) with the anti-PAF agent SRI 63-072. Int Arch Allergy Appl Immunol 1986;81:265-8.
13. 13. Patterson R, Harris KE, Krell RD. Effect of leukotriene D4 (LTD4) antagonist on LTD4 and ascaris antigen induced airway responses in rhesus monkeys. Int Arch Allergy Appl Immunol 1988;86:440-5.
14. 14. Patterson R, Harris KE, Bernstein PR, Krell RD, Handley DA, Saunders RN. Effects of combined receptor antagonists of leukotriene D4 (LTD4) and platelet-activating factor (PAF) on rhesus airway responses to LTD4, PAF and antigen. Int Arch Allergy Appl Immunol 1989;88:462-70.
15. 15. Hogan MB, Harris KE, Protter AA, Patterson R. A bradykinin antagonist inhibits both bradykinin and the allergen-induced airway response in primates. Proc Assoc Am Physicians 1997;109:269-74.
16. 16. Creticos PS, Van Metre TE, Mardiney MR, Rosenberg GL, Norman PS, Adkinson NF. Dose response of IgE and IgG antibodies during ragweed immunotherapy. J Allergy Clin Immunol 1984;73:94-104.
17. 17. Bienenstock J, Croitoru K, Ernst PB, Stead RH, Stanisz A. Neuroendocrine regulation of mucosal immunity. Immunol Invest 1989;18:69-76.
18. 18. Pascual DW, Bost KL, Xu-Amano J, Kiyono H, McGhee JR. The cytokine-like action of substance P upon B cell differentiation. Regul Immunol 1992;4:100-4.
19. 19. Kimata H, Yoshida A, Fujimoto M, Mikawa H. Effect of vasoactive intestinal peptide, somatostatin, and substance P on spontaneous IgE and IgG4 production in atopic patients. J Immunol 1993;150:4630-40.
20. 20. Payan DG, Brewster DR, Goetzl EJ. Specific stimulation of human T lymphocytes by substance P. J Immunol 1983;131:1613-5.
21. 21. Covas MJ, Pinto LA, Pereira da Silva JA, Victorino RMM. Effects of the neuropeptide, substance P, on lymphocyte proliferation in rheumatoid arthritis. J Int Med Res 1995;23:431-8.
22. 22. Baumgarten CR, Witzel A, Kleine-Tebbe J, Kunkel G. Substance P enhances antigen-evoked mediator release from human nasal mucosa. Peptides 1996;17:25-30.
23. 23. Schratzberger P, Reinisch N, Prodinger WM, Kähler CM, Sitte BA, Bellmann R, et al. Differential chemotactic activities of sensory neuropeptides for human peripheral blood mononuclear cells. J Immunol 1997;158:3895-901.
24. 24. Numao T, Agrawal DK. Neuropeptides modulate human eosinophil chemotaxis. J Immunol 1992;149:3309-15.
25. 25. Okamoto Y, Shirotori K, Kudo K, Ishikawa K, Ito E, Togawa K, et al. Cytokine expression after the topical administration of substance P to human nasal mucosa. The role of substance P in nasal allergy. J Immunol 1993;151:4391-8.
26. 26. Rameshwar P, Gascon P, Ganea D. Stimulation of IL-2 production in murine lymphocytes by substance P and related tachykinins. J Immunol 1993;151:2484-96.
27. 27. Suzuki H, Miura S, Liu YY, Tsuchiya M, Ishii H. Substance P induces degranulation of mast cells and leukocyte adhesion to venular endothelium. Peptides 1995;16:1447-52.
28. 28. Goetzl EJ, Cheng PPJ, Hassner A, Adelman DC, Frick OL, Sreedharan SP. Neuropeptides, mast cells and allergy: novel mechanisms and therapeutic possibilities. Clin Exp Allergy 1990;20(suppl 4):3-7.
29. 29. Alber G, Scheuber PH, Reck B, Sailer-Kramer B, Hartmann A, Hammer DK. Role of substance P in immediate-type skin reactions induced by staphylococcal enterotoxin B in unsensitized monkeys. J Allergy Clin Immunol 1989;84:880-5.
30. 30. Shanahan F, Denburg JA, Fox J, Bienenstock J, Befus D. Mast cell heterogeneity: effects of neuroenteric peptides on histamine release. J Immunol 1985;135:1331-7.
31. 31. Pascual DW, Xu-Amano J, Kiyono H, McGhee JR, Bost KL. Substance P acts directly upon cloned B lymphoma cells to enhance IgA and IgM production. J Immunol 1991;146:2130-6.
32. 32. Payan DG, Goetzl EJ. Modulation of lymphocyte function by sensory neuropeptides. J Immunol 1985;135(suppl):783S-6S.
33. 33. Payan DG, Brewster DR, Missirian-Bastian A, Goetzl EJ. Substance P recognition by a subset of human T lymphocytes. J Clin Invest 1984;74:1532-9.
34. 34. Hart R, Dancygier H, Wagner F, Lersch C, Classen M. Effect of substance P on immunoglobulin and interferon-gamma secretion by cultured human duodenal mucosa. Immunol Lett 1990;23:199-204.
35. 35. Stanisz AM, Scicchitano R, Dazin P, Bienenstock J, Payan DG. Distribution of substance P receptors on murine spleen and Peyer's patch T and B cells. J Immunol 1987;139:749-54.
36. 36. Blum AM, Metwali A, Cook G, Mathew RC, Elliot D, Weinstock JV. Substance P modulates antigen-induced, IFNγ production in murine Schistosomiasis mansoni. J Immunol 1993;51:225-33.
37. 37. Blum AM, Metwali A, Mathew PC, Elliot D, Weinstock JV. Substance P and somatostatin can modulate the amount of IgG 2a secreted in response to schistosome egg antigen in murine Schistosomiasis mansoni. J Immunol 1993;151:6994-7004.
38. 38. Carucci JA, Auci DL, Herrick CA, Durkin HG. Neuropeptide-mediated regulation of hapten-specific suppression of BPO-specific IgE antibody-forming cell responses induced in vivo and in vitro. J Leukocyte Biol 1995;57:110-5.
39. 39. Carucci JA, Herrick CA, Durkin HG. Neuropeptide-mediated regulation of hapten-specific IgE responses in mice. II. Mechanisms of substance P-mediated isotype-specific suppression of BPO-specific IgE antibody-forming cell responses induced in vitro. J Neuroimmunol 1994;49:89-95.
40. 40. Kiney-Cain T, Bost KL. Substance P-induced IL-12 production by murine macrophages. J Immunol 1997;158:2334-9.
41. +T cell clones mediate the in vivo inhibition of rat IgE. J Immunol 1998;160:580-7.
42. +T cells following the primary immunization with ovalbumin response results in a high and persistent IgE response in IgE hyporesponsive rats. Int Arch Allergy Immunol 1997;113:160-2.
43. 43. Finotto S, Mekori YA, Metcalfe DD. Glucocorticoids decrease tissue mast cell number by reducing the production of the c-kit ligand, stem cell factor, by resident cells. In vitro and in vivo evidence in murine systems. J Clin Invest 1997;99:1721-8.
44. 44. Lantz CS, Yamaguchi M, Oettgen HC, Katona IM, Miyajima I, Kinet J-P, et al. IgE regulates mouse basophil FcεRI expression in vivo. J Immunol 1997;158:2517-21.
45. 45. Bernstein JA. Antihistamines. In: Patterson R, Grammer LC, Greenberger PA, editors. Allergic diseases: diagnosis and management. 5th ed. Philadelphia: Lippincott-Raven; 1997. p. 59-74.
46. 46. Hogan MB, Harris KE, Protter A, Patterson R. A bradykinin antagonist inhibits both the bradykinin-and the allergen-induced airway response in primates. Proc Assoc Am Physicians 1997;109:269-74.
47. 47. Carballido JM, Aversa G, Kaltoft K, Cocks BG, Punnonen J, Yssel H, et al. Reversal of human allergy T helper 2 responses by engagement of signaling lymphocytic activation molecule. J Immunol 1997;159:4316-21.
48. 48. El-Shazly AE, Masuyama K, Eura M, Ishikawa T. Immunoregulatory effect of substance P in human eosinophil migratory function. Immunol Invest 1996;25:191-201.
49. 49. Hart R, Dancygier H, Wagner F, Niedermeyer H, Classen M. Substance P modulates lymphokine activities in supernatants of cultured human duodenal biopsies. Immunol Lett 1988;19:133-6.
50. 50. Lichtenstein LM. Histamine-releasing factors and IgE heterogeneity. J Allergy Clin Immunol 1988;81:814-20.
51. 51. Fiebiger E, Hammerschmid F, Stingl G, Maurer D. Anti-FcεRIα autoantibodies in autoimmune-mediated disorders. Identification of a structure-function relationship. J Clin Invest 1998;101:243-51.